.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
Healthtrust
QuintilesIMS
Deloitte
Citi
Johnson and Johnson
Accenture
Cipla
Novartis

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,741,881

« Back to Dashboard

Which drugs does patent 8,741,881 protect, and when does it expire?


Patent 8,741,881 protects ANDROGEL and is included in one NDA. There have been three Paragraph IV challenges on Androgel.

This patent has twenty-eight patent family members in twenty-six countries.

Summary for Patent: 8,741,881

Title:Testosterone gel and method of use
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Inventor(s): Malladi; Ramana (Marietta, GA), Stahlman; Jodi (Smyrna, GA)
Assignee: Unimed Pharmaceuticals, LLC (Marietta, GA) Besins Healthcare Luxembourg, SARL (Charlotte, LU)
Application Number:13/831,231
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AbbvieANDROGELtestosteroneGEL, METERED;TRANSDERMAL022309-001Apr 29, 2011ABRXYesYes► Subscribe► Subscribe► SubscribeTESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
AbbvieANDROGELtestosteroneGEL;TRANSDERMAL022309-002Sep 7, 2012AB2RXYesNo► Subscribe► Subscribe► SubscribeTESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
AbbvieANDROGELtestosteroneGEL;TRANSDERMAL022309-003Sep 7, 2012AB2RXYesYes► Subscribe► Subscribe► SubscribeTESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,741,881

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,759,329Testosterone gel and method of use► Subscribe
8,466,136Testosterone gel and method of use► Subscribe
8,754,070Testosterone gel and method of use► Subscribe
8,486,925Testosterone gel and method of use► Subscribe
8,729,057Testosterone gel and method of use► Subscribe
8,466,138Testosterone gel and method of use► Subscribe
8,466,137Testosterone gel and method of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,741,881

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine87627► Subscribe
TunisiaSN08167► Subscribe
Slovenia1937276► Subscribe
Serbia52671► Subscribe
Portugal1937276► Subscribe
New Zealand567056► Subscribe
Norway20082170► Subscribe
Morocco29941► Subscribe
South Korea20080068654► Subscribe
Japan5728508► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Covington
Boehringer Ingelheim
Daiichi Sankyo
Healthtrust
Fuji
Baxter
Merck
Cipla
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot